| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
TLR9 (Toll‑like receptor 9) in mice. ODN 1585 is a class A CpG ODN that specifically activates mouse TLR9. It does not cross‑react with human TLR9.
|
|---|---|
| ln Vitro |
In cell‑free assays, ODN 1585 binds to and activates mouse TLR9. In cellular assays, ODN 1585 sodium (0.1‑10 uM) potently induces the production of IFN‑alpha, IFN‑beta, and TNF‑alpha in mouse immune cells. It is a potent stimulator of NK cells and enhances the function of CD8+ T cells, including increasing CD8+ T cell‑mediated IFN‑gamma production.
|
| ln Vivo |
In vivo, ODN 1585 sodium induces regression of established melanoma tumors in mice. It has also been shown to confer complete protection against malaria in mice, likely through the induction of potent immune responses. It can be used as a vaccine adjuvant to enhance the immunogenicity of co‑administered antigens.
|
| Enzyme Assay |
A general cell‑free protocol for assessing TLR9 activation is not available. However, the binding of ODN 1585 to TLR9 can be assessed using a surface plasmon resonance (SPR) assay. Recombinant mouse TLR9 protein is immobilized on a sensor chip, and varying concentrations of ODN 1585 are flowed over the chip. The association and dissociation rates are measured, and the Kd is calculated.
|
| Cell Assay |
General cellular protocol for ODN 1585 sodium: Mouse splenocytes or bone marrow‑derived dendritic cells (BMDCs) are seeded in 24‑well plates at 1×10⁶ cells/well. Cells are treated with ODN 1585 sodium (0.01, 0.1, 1, 10 uM) for 24 hours. The culture supernatant is collected, and cytokine levels (IFN‑alpha, TNF‑alpha, IL‑6, IL‑12) are measured by ELISA. For NK cell activation, mouse splenocytes are treated with ODN 1585 for 24 hours, and the percentage of CD69+ NK1.1+ cells is measured by flow cytometry. For CD8+ T cell function, splenocytes are treated with ODN 1585 and the percentage of CD8+ T cells producing IFN‑gamma is measured by intracellular cytokine staining after flow cytometry.
|
| Animal Protocol |
A general animal protocol for ODN 1585 sodium: For the B16‑F10 melanoma model, C57BL/6 mice are subcutaneously implanted with B16‑F10 cells (5×10⁵). When tumors are established (~5‑7 days), mice are randomized (n=10/group). ODN 1585 sodium is formulated in sterile PBS and administered via intratumoral (IT) injection at doses of 10, 50, and 100 ug/mouse on days 7, 10, and 14. Tumor growth is monitored, and survival is recorded. For the malaria model, mice are administered ODN 1585 (50 ug/mouse, IP) 2 days prior to infection with Plasmodium yoelii. Parasitemia is monitored by blood smear, and survival is recorded.
|
| ADME/Pharmacokinetics |
General PK protocol for ODN 1585 sodium: ODN 1585 is administered to mice via intraperitoneal (IP, 10 mg/kg) and intravenous (IV, 5 mg/kg) routes. Blood samples are collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours. Plasma concentrations of the ODN are quantified by a hybridization LC‑MS/MS assay. PK parameters (Cmax, Tmax, AUC, t1/2, clearance, Vd, and IP bioavailability) are calculated.
|
| Toxicity/Toxicokinetics |
General toxicity protocol for ODN 1585 sodium: A 14‑day repeat‑dose IP toxicity study is performed in ICR mice. ODN 1585 is administered at doses of 10, 30, and 100 mg/kg/day. Parameters include clinical signs, body weight, food consumption, hematology (CBC with differential), serum chemistry (ALT, AST, BUN, creatinine), and histopathology of major organs (liver, kidney, spleen, lymph nodes). Cytokine profiling (IFN‑alpha, TNF‑alpha, IL‑6) is performed to assess immune activation.
|
| Additional Infomation |
spleen and lymph node histology is examined for signs of lymphoid hyperplasia.
|
| Molecular Weight |
6889.80
|
|---|---|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1451 mL | 0.7257 mL | 1.4514 mL | |
| 5 mM | 0.0290 mL | 0.1451 mL | 0.2903 mL | |
| 10 mM | 0.0145 mL | 0.0726 mL | 0.1451 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
